Bliss GVS Pharma (506197) Q2 24/25 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024, were approved.

• Mr. Nandkumar Kashinath Chodankar appointed as Chairman of the Board effective October 24, 2024.

• Changes in senior management personnel due to internal reporting structure updates.

Financial highlights

• Consolidated revenue for the quarter ended September 30, 2024, was ₹21,767.95 lakh, up from ₹18,364.27 lakh year-over-year.

• Consolidated net profit for the quarter was ₹2,569.25 lakh, compared to ₹2,210.68 lakh in the same quarter last year.

• Earnings per share (basic) for the quarter stood at ₹2.31, up from ₹1.97 year-over-year.

• Total comprehensive income for the quarter was ₹2,389.59 lakh.

Outlook and guidance

• The company remains committed to regulatory compliance and may appeal regulatory fines if necessary.